

Expression of CK19 in papillary thyroid carcinoma in comparison with benign thyroid lesions

Thura Abbas Fadhel (FIBMS)¹

¹ College of Medicine , University of Diyala , Iraq

Abstract

OPEN ACCESS

Correspondence Address: Thura Abbas Fadhel

College of Medicine , University of Diyala , Iraq

Email: Thuraa@uodiyala.edu.iq

Copyright: ©Authors, 2023, Collage of Medicine, University of Diyala. This is an open access article under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license

(<http://creativecommons.org/licenses/by/4.0/>)

Website:

<https://djm.uodiyala.edu.iq/index.php/djm>

Received: 11 October 2022

Accepted: 20 November 2022

Published: 5 April 2023

Background: The Papillary variant of thyroid carcinoma is one of the common types of thyroid malignancies , the commonest. Its diagnosis usually is microscopic which based on nuclear features.

Objective: To assess the immunohistochemical expression of cytokeratin 19 (CK19) in PTC and compare its reactivity with other thyroid conditions to approve its importance as a useful test for diagnosing PTC.

Patients and Methods: Twenty- cases of papillary thyroid carcinoma (with different variants), five follicular adenomas and ten multinodular goiters (MNG) were collected over three years (2018-2021).10% formalin-fixed sections were collected from thyroidectomy specimens. Stained with Hematoxylin and eosin then immunohistochemical staining for immune-marker CK 19 was done using standard techniques. The results were quantitatively scored as the following: score 0 (negative) , score 1+ (<5%) positive cells), score 2+ (5- 25%), score 3+ (25-75%) ,finally score 4+ (>75%) positive cells), and then calculated.

Results: An 18 (90%) papillary carcinomas show diffuse and strong (3+ and 4+) expression of CK19 . ,three out of ten (30%) MNG were weakly positive(1+ and 2+) and focal in distribution while in follicular adenoma all cases were negative for CK19 .

Conclusion: Ck 19 can stain benign and malignant thyroid tissue, but strong membranous staining applied in cases of papillary ca , thus can be used as confirmatory tool for PTC diagnosis.

Keywords: Cytokeratin 19, thyroid, papillary thyroid carcinoma, immunostaining , histopathology, MNG

Introduction

Papillary thyroid carcinoma (PTC) is the most common type (80-93%) of thyroid carcinomas [1] , characterized by the nuclear features , such as change of nuclear size; nuclear enlargement, change in nuclear shape with overlapping in addition to chromatin margination and clearing [2]. Nuclear membrane changes include irregular nuclear membrane, a nuclear grooving with nuclear pseudo inclusion [3]. There are Fifteen

variant of papillary thyroid carcinoma, one of them is the classic papillary thyroid types , as stated in the 2017 WHO classification [4].

Due to the widely available and safety usage of ultrasound, there is increment in the diagnosis of papillary thyroid carcinoma in the last 25 years due to early diagnosis of thyroid nodules by radiological tools like (ultrasound and CT), which is called the

thyroid cancer epidemics ; most of them at early stages [6].

Nearly all thyroid disorders including PTC are of female predominance with Female : male ratio of 3 to 1 [7].

At the microscopic level, the most common microscopic variant are classic PTC, micro-carcinoma, follicular type of papillary ca [8]. Occult (subclinical) tumors can be found in 6% at autopsy (<10 mm), 46.6% can be multicentric, and 14% present with nodal metastasis [8].

Occult tumors are usually with male predominance [7].

Diagnosis of papillary thyroid ca is typically reached by using pre-operative fine needle aspiration cytology based on the finding of the typical nuclear features.

The Molecular study of cytological aspirates may assist in the preoperative diagnosis of the malignancy [10].

Diagnosis of thyroidectomy specimen again based on finding the nuclear features, including alteration of nuclear size, and shape, alteration in chromatin (clumping) and nuclear membrane irregularity (groove and inclusion) [10] as shown in the following Figure (1).




Figure (1):Show the microscopic feature of papillary thyroid ca like nuclear groove (black arrow), ground glass nucleus (blue arrow), and pseudoinclusion (red arrow)

There are many antibodies (immunohistochemical stains) available that are positive for thyroid cells like .Cytokeratin AE1/AE3,CK7,TTF1,PAX8,and thyroglobulin BRAF is positive test for PTC [10]. The utility Of CK19 to differentiate malignant from benign ones remains not clearly defined [11,12,13].

Other specific immunohistochemical stains include CDX2 ; used for the columnar cell variant (+ve in 50% of cases [14] and Ki67 index if more than 10% with aggressive tumors with high recurrence rate [15].

Patients and Methods

In this descriptive retrospective study a total of Thirty-Five cases of excisional thyroid biopsies were collected over 3 years from 2018 to 2020. The cases were already diagnosed by Hematoxylin-eosin stain and retrieved from the archive of AL-Shaheed Ghazi AL-Hariri Hospital. After that the immuno_histochemical stains were applied on 5-µm-thick paraffin sections on negatively charged slides. A Primary antibody for CK19 was applied for each section.

Positive control : ductal breast cells. Negative control ; Hepatocytes (as recommended by the leaflet). Evaluation of staining : positive staining of CK19 considered when a

membranous and/or cytoplasmic staining pattern of cells with brown color. Expression t of CK19 staining was quantitatively scored as shown in the following [16].

Table (1): Show the semiquantitative scoring of CK19 antibody in to five scores according to the number of cells taking stain [16]

No. of + stained cells	Score of CK19
No cells	0
< 5	1+
5-25	2+
25-75	3+
> 75	4+

Statistical Analysis

The included data in this study were statistically calculated according the proportions, percentage , ratio and range methods by using 2007 window program.

Results


Forty-five patients with recurrent inguinal Clinicopathological Analysis : Thirty- five cases of thyroidectomy were included in this retrospective study.Their age was ranging from 27-55 y with the most frequent age (50%) were in the 3rd decade of life. Regarding patients sex ; male to female ratio

was (1:1.4). The predominant microscopic type was papillary thyroid ca , usual type (15) case, (42%) , follicular variant of ca was 5 (14%) , follicular adenoma was 5 (14%), and multinodular goiter 10 cases (28%) .

Correlation between CK19 and type of tumors : in this descriptive study , the majority of cases were of PTC that all show high scores (3+, 4+) of positivity as mentioned in this Table (2), Figure (2) other lesions present with focal and patchy expression or negative one.

Table (2): The expression of CK19 in different thyroid lesions with intense expression in cases of papillary thyroid ca and the least score 0 in benign goiter and follicular adenoma

CK19 score	No. of cases	Microscopic type
0	12	6 multinodular goiter , 5 follicular adenoma 1 PTC
1+	4	4 multinodular goiter
2+	4	PTC
3+	6	PTC
4+	9	PTC



Figure(2):Showing the intense membranous expression of CK19 in papillary thyroid ca. score 4+



Figure(3):Showing the negative expression of CK19 in follicular adenoma , score 0

Correlation between CK19 and patient age : there is no correlation between age and CK19 score. Correlation between CK19 and sex of the patients : results show there is good correlation between sex and score. High score cases were with female , which is the largest group in PTC patients. Correlation between the sex and histopathological type: results show there is increasing in the malignant types of thyroid lesions (PTC) in females rather than males.

Discussion

Gender distribution : in this retrospective study , we found that are all types included in our study were of female predominance . the male\female ratio (1\1.4) which go with Rebecca L Siegel *et al* [16] in which there is 3 : 1 female to male ratio despite the higher NO. of patient used by them. Also compatible with Karrison LeClair *et al* eho

search for subclinical cases was 14% in women and 12% in males from the total subclinical thyroid lesion at autopsy [17] , but there is no correlation between CK19 expression and sex of patients.

CK19 in benign lesions: the he types of benign diseases included in this study were the follicular adenoma and multinodular goiters due to their microscopical variation including papillary and micropapillary features , the expression of the immunohistochemical stain CK19 was negative in the majority of cases (7) which represent 50% of the non-malignant cases and 50% were weakly positive (score 1+ , 2+). These results agree with the study of Noroozinia *et al* that show CK19 negative in most cases of follicular adenoma [18].

CK19 in malignant lesions ; the results of our study show positive CK19 expression

and the malignant nature of thyroid lesions specifically PTC (75%) with diffuse and intense expression, (20%) with focal positivity, and only (5%) negative which may be due to technical errors. Which are the same result done by Asmaa Gaber Abdou *et al* in which there is 92.9% positivity to CK19 in PTC cases, with most follicular adenomas were negative [19]. In the study of Suna Arkilic MD; all the cases of PTC were diffusely and intensely positive for CK19, while the cases of follicular adenoma and multinodular goiter were negative and a minority of 8% stained positive [20].

The results of John N Flanagan *et al* strengthen our study by confirming all cases of PTC intense and diffuse membranous staining in CK19 with negative staining in multinodular goiter [21].

Conclusions

1. CK19 expression in 95% of studied PTC cases with various score of expression (2+__4+).
2. The expression of CK19 was 100% negative in follicular adenoma and focal, patchy in some cases of multinodular goiter.
3. CK19 can be used to determine the benign from the malignant thyroid diseases.
4. There is positive correlation between patients sex and CK19 score.

Recommendations

The present study suggests that CK19 is a good useful marker for confirmation diagnosis of papillary thyroid carcinoma at the microscopic level.

Acknowledgments

The author thanks the Ministry of Higher Education and Scientific Research of Iraq for their continuous supports, and special

thanks to the Al Shaheed Gazi Alhariri hospital for their permission to collect data.

Source of funding: The current study was funded by our charges with no any other funding sources elsewhere.

Ethical clearance: Ethical approval was obtained from the College of Medicine / University of Diyala ethical committee for this study.

Conflict of interest: Nil

References

- [1] Barwad A, Ramtekke PP, Gamanagatti S, Pappillary thyroid carcinoma present as scalp metastasis. *J Cytol.* 2018 Apr-Jun;35(2):126
doi:10.4103/JOC.JOC_133-17.PMID:29643664;PMCID:PMC5885603.
- [2] Recardo V, Lioyd, Robert Y, Osamura, Genter Kloppel, Juan Rosai, WHO classification of tumors, Health Organization; 4th edition (July 26, 2017) (ISBN-13:978-9283244936)
- [3] Vinay Kamar, Abul Abbas, Jon Aster; Robbin Basic Pathology, 10th edition, March 8, 2017. ELSEVIER
- [4] Edmund S Cibas, Barbara S. Ducatman-Diagnostic Principles and Clinical Correlates. 5th edition 5 December 2019. Elsevier.
- [5] John R. Goldblum, Jessi K Mckenney, Laura W. Lamps, Jeffery L. Myers. Rosai and Ackerman Surgical pathology. 11th edition, 2018. Elsevier
- [6] Heong Sik Ahn, H Gilbert Welch, South Korea thyroid cancer. *N Engl J Med.* 2015 December 10;373(24):2389-90, doi:10.1056/NEJMC1507622
- [7] Kimberly D Miller, Rebecca L Seigel, Ahmadin Jamal; Cancer statistics, *CA Cancer J Clin.* 2018 Jan;68(1):7-30. Doi:10.3322/caac.21442. Epub 2018 Jan 4.

- [8] W Lang , H Borrash , L Bauer, Occult ca of thyroid, *Am J Clin Pathol*, 1988 Jul;90(1):72-6.doi:10.1039\ajcp\90.1.72.
- [9] A Fink , G Tomlison , J L Freeman , I B Rosen, S L Asa, Occult micropapillary ca, *Mod Pathol J* 1996 August;9(8):816-20
- [10] Bin Xo , Rene Serrete, R Mechaal Tuttle, Bayan Alzumaili, Ian Ganly, Nora Katabi *et al.* Papilli in conventional papillary ca. *Tyroid*. 2019 December;29(12):1792-1803.doi:10.1089\thy.2019.0328.Epub 2019Oct 10.
- [11] Cerilli , L A., Mills, S. E., Rumpel, C. A., Dudley, T. H., Moskaluk. Interpretation of RETimmunostain. *American Journal of clinical pathology* ,118(2),186-193, doi.org\10.1309\53UC-4U88-RRTN.
- [12] S Sahoo, S A Hoda, J Rosai, R A Delellis. CK19 immunoreactivity in PTC . *Am J Clin pathol*. 2001 Nov,116(5):696-702.doi:10.1309\6D9D-7JCM-X4T5-NNJY.
- [13] Scognamiglio, T., Hyjek, E. , Kao, J. ,Chen Y. T. 2006, Diagnostic usefulness of HBME1,CK19 in encapsulated lesion of PTC. *Merican Journal of clinical pathology*,126(5),700-708.
- [14] Baloch ZW, livolsi VA , Special types of thyroid ca. *Histopathology*. 2018;72(1):40-52.doi:10.1111\his.13348.
- [15] Matsuse MM Yabuta TM Seanko V, Mitsuyoshi Hirokawa, Eijun Nishihara, Keiji Suzuki *et al.* Ki 67 prognostic marker in PTC. *Sci Rep*. 2017;7:41752. Feb 2, doi:10.1083\srep41752.
- [16] Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid cancer epidemic. *N Engl J Med*. 2016;375(7):614-617. Doi:10.1056\NEJMP1604412.
- [17] Karissa LeClair, BS1; Katy J. L. Bell, MBChB, MMed, PhD2 *et al* . *JAMA Intern Med*. 2021;181(10):1351-1358. doi:10.1001/jamainternmed.2021.4804
- [18] F. Noroozinia, A. Gheibi, B. Ilkhanizadeh, and A. Abbasi* --- *Acta Endocrinol (Buchar)*. 2016 Oct-Dec; 12(4): 387–391. doi: 10.4183/aeb.2016.387
- [19] Abdou AG, Shabaan M, Abdalha R, Nabil N. Diagnostic Value of TROP-2 and CK19 Expression in Papillary Thyroid Carcinoma in Both Surgical and Cytological Specimens. *Clinical Pathology*. 2019;12. doi:10.1177/2632010X19863047
- [20] Erkiliç, S., Aydın, A. & Emrah Koçer, N. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. *Endocr Pathol* 13, 207–211 (2002). doi.org/10.1385/EP:13:3:207.
- [21] John N. Flanagan, Pedro Pineda, Philip E. Knapp, Antonio De Las Morena *et al* , Expression of Cytokeratin 19 in the Diagnosis of Thyroid Papillary Carcinoma by Quantitative Polymerase Chain Reaction. *Endocrine Practice*. 2008 vol 14(2):168-174.doi:10.4158\EP.14.2.168.

التعبير المناعي للدالة CK19 في الاورام الحليمية الخبيثة للغدة الدرقية ومقارنتها مع الاورام الحميدة

ذرى عباس فاضل^١

الملخص

خلفية الدراسة: تعتبر الاورام الحليمية الخبيثة للغدة الدرقية من اكثر الاورام شيوعا فيها ويعتمد تشخيصها على المواصفات والتغيرات المجهرية في النواة.

اهداف الدراسة: لبيان التعبير المناعي للدالة CK19 في الاورام الخبيثة الحليمية للغدة الدرقية ودراستها في الاورام الحميدة والمقارنة بينهم وامكانية استخدام الداله في تشخيص هذا النوع من السرطانات.

المرضى والطرائق: عشرون حالة من اورام الغدة الدرقية الحليمية تشمل خمسة اورام جريبية و عشرة اورام عقدية و جمعت طوال ثلاث سنوات من الارشيف الخاص بمختبرات مستشفى الشهيد غازي الحريري للجراحات التخصصية . النماذج الماخوذه كانت مشخصه مسبقا من قبل اخصائي المستشفى وتم اعادة صبغها بالصبغه الروتينيه و ثم صبغها بالداله المناعية CK19 وتم حساب النتائج وفق التالي : بلاصبغه (٠) ، اقل من ٥% (رقم ١) ، من ٥-٢٥% (رقم ٢) ، من ٥٠-٧٥% (رقم ٣) واكثر من ٧٥% (رقم ٤).

النتائج: وجدنا ١٨ حالة اي مايقارب ٩٠% من الورم الحليمي للغدة الدرقية اظهروا صبغه قويه لل ck19 (رقم ٣ و ٤)، ثلاثة من اصل عشرة حالات للورم العقدي اظهروا صبغه متوسطه (رقم ١ و ٢) واخيرا الورم الجريبي الحميد لم يظهر ايه استجابته للداله المناعية.

الاستنتاجات: الداله المناعية CK19 ممكن ان تصبغ الحالات السرطانية والحميدة للغدة الدرقية بدرجات متفاوتة ولكن الصبغه تكون قوية في حالات سرطان الغدة الدرقية الحليمي لذلك ممكن ان تستخدم في التشخيص النهائي للمرض.

الكلمات المفتاحية: الداله المناعية CK19 ، الغدة الدرقية، السرطان الحليمي ، الفحص النسيجي ، التعبير المناعي، الورم العقدي

البريد الالكتروني: Thuraa@uodiyala.edu.iq

تاريخ استلام البحث: ١١ تشرين الاول ٢٠٢٢

تاريخ قبول البحث: ٢٠ تشرين الثاني ٢٠٢٢

^١ كلية الطب - جامعة ديالى - ديالى - العراق